Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells

Trends in Molecular Medicine

Volumn 16, Issue 1, 2010, Pages 17-26

  Sang, Liyun ^a   Roberts, James M ^b   Coller, Hilary A ^c  

^a GENENTECH INC   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; NOTCH RECEPTOR; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR HES 1;

APOPTOSIS; BHLH GENE; CANCER THERAPY; CELL AGING; CELL DIFFERENTIATION; CELL FATE; DRUG TARGETING; FIBROBLAST; GENE; GENE EXPRESSION; GENE REPRESSION; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; REVIEW; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TREATMENT PLANNING; TUMOR CELL;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL CYCLE; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HOMEODOMAIN PROTEINS; HUMANS; NEOPLASMS; PROTEIN BINDING;

ERINACEIDAE;

EID: 73449115693     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2009.11.001     Document Type: Review

References (104)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
2. Holyoake T., et al. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94 (1999) 2056-2064
3. Jorgensen H.G., et al. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia 19 (2005) 1184-1191
4. Karantza-Wadsworth V., et al. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev. 21 (2007) 1621-1635
5. White E., et al. The double-edged sword of autophagy modulation in cancer. Clin. Cancer Res. 15 (2009) 5308-5316
6. Wikman H., et al. Cancer micrometastasis and tumour dormancy. APMIS 116 (2008) 754-770
7. Gray J.V., et al. "Sleeping beauty": quiescence in Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev. 68 (2004) 187-206
8. Yusuf I., et al. Regulation of quiescence in lymphocytes. Trends Immunol. 24 (2003) 380-386
9. Venezia T.A., et al. Molecular signatures of proliferation and quiescence in hematopoietic stem cells. PLoS Biol. 2 (2004) e301
10. Iyer V.R., et al. The transcriptional program in the response of human fibroblasts to serum. Science 283 (1999) 83-87
11. Coller H.A., et al. A new description of cellular quiescence. PLoS Biol. 4 (2006) e83
12. Sang L., et al. Control of the reversibility of cellular quiescence by the transcriptional repressor HES1. Science 321 (2008) 1095-1100
13. Sang L., et al. Fear of commitment: HES1 protects quiescent fibroblasts from irreversible cellular fates. Cell Cycle 8 (2009) 2161-2167
14. Kageyama R., et al. Roles of bHLH genes in neural stem cell differentiation. Exp. Cell Res. 306 (2005) 343-348
15. Ishibashi M., et al. Targeted disruption of mammalian Hairy and Enhancer of Split homolog-1 (HES-1) leads to upregulation of neural helix-loop-helix factors, premature neurogenesis and severe neural tube defects. Genes Dev. 9 (1995) 3136-3148
16. Kageyama, et al. The bHLH gene Hes1 regulates differentiation of multiple cell types. Mol. Cells 10 (2000) 1-7
17. Abderrahmani A., et al. The Hairy and Enhancer of Split 1 is a negative regulator of the repressor element silencer transcription factor. FEBS Lett. 579 (2005) 6199-6204
18. Klonisch T., et al. Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol. Med. 14 (2008) 450-460
19. Lowe S.W., et al. Intrinsic tumour suppression. Nature 432 (2004) 307-315
20. Hansson E.M., et al. Notch signaling in development and disease. Semin Cancer Biol. 14 (2004) 320-328
21. Campos-Ortega J.A., et al. Molecular analysis of a cellular decision during embryonic development of Drosophila melanogaster: epidermogenesis or neurogenesis. Eur. J. Biochem. 190 (1990) 1-10
22. Bolos V., et al. Notch signaling in development and cancer. Endocr. Rev. 28 (2007) 339-363
23. Wang Z., et al. Emerging role of Notch in stem cells and cancer. Cancer Lett. 279 (2009) 8-12
24. Mumm J.S., et al. Notch signaling: from the outside in. Dev. Biol. 228 (2000) 151-165
25. Ohtsuka T., et al. HES1 and HES5 as Notch effectors in mammalian neuronal differentiation. Embo. J. 18 (1999) 2196-2207
26. Grbavec D., et al. Molecular interaction between TLE1 and the carboxyl-terminal domain of HES-1 containing the WRPW motif. Biochem. Biophys Res. Commun. 223 (1996) 701-705
27. Dontu G., et al. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 6 (2004) R605-615
28. van Es J.H., et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435 (2005) 959-963
29. Duncan A.W., et al. Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat. Immunol. 6 (2005) 314-322
30. Katoh M. Integrative genomic analyses on HES/HEY family: Notch-independent HES1, HES3 transcription in undifferentiated ES cells and Notch-dependent HES1, HES5, HEY1, HEY2, HEYL transcription in fetal tissues, adult tissues or cancer. Int. J. Oncol. 31 (2007) 461-466
31. Bolos V., et al. Notch signalling in cancer stem cells. Clin. Transl. Oncol. 11 (2009) 11-19
32. Weng A.P., et al. Activating mutations of NOTCH1 in human T-cell acute lymphoblastic leukemia. Science 306 (2004) 269-271
33. Lee S.Y., et al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci. 100 (2009) 920-926
34. Farnie G., et al. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J. Natl. Cancer Inst. 99 (2007) 616-627
35. Casalbore P., et al. Tumorigenic potential of olfactory bulb-derived human adult neural stem cells associates with activation of TERT and NOTCH1. PLoS One 4 (2009) e4434
36. Rasul S., et al. Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells. Br. J. Cancer 100 (2009) 1879-1888
37. Tanaka M., et al. Inhibition of Notch pathway prevents osteosarcoma growth by cell-cycle regulation. Br. J. Cancer 100 (2009) 1957-1965
38. Rao S.S., et al. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell-cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res. 69 (2009) 3060-3068
39. Fan X., et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 66 (2006) 7445-7452
40. Hoey T., et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell (2009) 5
41. Deangelo, D.J. et al. (2006) A phase I clinical trial of the Notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. In ASCO Annual Meeting., Abstract No: 6585
42. Krop, I.E. et al. (2006) Phase I pharockinetic (PK) and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors. In ASCO Annual Meeting, Abstract No: 10574
43. Ingram W.J., et al. Sonic Hedgehog regulates Hes1 through a novel mechanism that is independent of canonical Notch pathway signalling. Oncogene 27 (2008) 1489-1500
44. Wall D.S., et al. Progenitor cell proliferation in the retina is dependent on Notch-independent Sonic Hedgehog/Hes1 activity. J. Cell Biol. 184 (2009) 101-112
45. Adolphe C., et al. An in vivo comparative study of sonic, desert and Indian Hedgehog reveals that Hedgehog pathway activity regulates epidermal stem cell homeostasis. Development 131 (2004) 5009-5019
46. Briscoe J., et al. A Hedgehog-insensitive form of patched provides evidence for direct long-range morphogen activity of sonic Hedgehog in the neural tube. Mol. Cell 7 (2001) 1279-1291
47. Roessler E., et al. Mutations in the human Sonic Hedgehog gene cause holoprosencephaly. Nat. Genet. 14 (1996) 357-360
48. Ingham P.W., et al. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 15 (2001) 3059-3087
49. Jiang J., et al. Hedgehog signaling in development and cancer. Dev. Cell 15 (2008) 801-812
50. Hovhannisyan A., et al. From teratogens to potential therapeutics: natural inhibitors of the Hedgehog signaling network come of age. Planta Med. 75 (2009) 1371-1380
51. Goodrich L.V., et al. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 277 (1997) 1109-1113
52. Aszterbaum M., et al. Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. Nat Med 5 (1999) 1285-1291
53. Gailani M.R., et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 14 (1996) 78-81
54. Taylor M.D., et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 31 (2002) 306-310
55. Sheng T., et al. Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer 3 (2004) 29
56. Thayer S.P., et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425 (2003) 851-856
57. Qualtrough D., et al. Hedgehog signalling in colorectal tumour cells: induction of apoptosis with cyclopamine treatment. Int J Cancer 110 (2004) 831-837
58. Tanaka H., et al. The Hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24-/low subpopulation and the side population of breast cancer cells. Anticancer Res. 29 (2009) 2147-2157
59. Sims-Mourtada J., et al. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin. Cancer Res. 12 (2006) 6565-6572
60. Dembinski J.L., et al. Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin. Exp. Metastasis (2009)
61. Sims-Mourtada J., et al. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 26 (2007) 5674-5679
62. Garber K. Hedgehog drugs begin to show results. J. Natl. Cancer Inst. 100 (2008) 692-697
63. Feldmann G., et al. Blockade of Hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 67 (2007) 2187-2196
64. Bar E.E., et al. Cyclopamine-mediated Hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25 (2007) 2524-2533
65. Borzillo G.V., et al. The Hedgehog signaling pathway as a target for anticancer drug discovery. Curr. Top Med. Chem. 5 (2005) 147-157
66. Paroush Z., et al. Groucho is required for Drosophila neurogenesis, segmentation and sex determination and interacts directly with Hairy-related bHLH proteins. Cell 79 (1994) 805-815
67. Chen G., et al. A functional interaction between the histone deacetylase Rpd3 and the corepressor groucho in Drosophila development. Genes Dev. 13 (1999) 2218-2230
68. Wang G.G., et al. Chromatin remodeling and cancer, Part I: Covalent histone modifications. Trends Mol. Med. 13 (2007) 363-372
69. Fischer A., et al. Delta-Notch - and then? Protein interactions and proposed modes of repression by Hes and Hey bHLH factors. Nucleic Acids Res. 35 (2007) 4583-4596
70. Takata T., et al. Human Sir2-related protein SIRT1 associates with the bHLH repressors HES1 and HEY2 and is involved in HES1- and HEY2-mediated transcriptional repression. Biochem. Biophys Res. Commun. 301 (2003) 250-257
71. David G., et al. Specific requirement of the chromatin modifier mSin3B in cell-cycle exit and cellular differentiation. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 4168-4172
72. Grignani F., et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391 (1998) 815-818
73. Lo-Coco F., et al. Acute promyelocytic leukemia: recent advances in diagnosis and management. Semin Oncol. 35 (2008) 401-409
74. Haumaitre C., et al. Directing cell differentiation with small molecule histone deacetylase inhibitors: the example of promoting pancreatic endocrine cells. Cell Cycle 8 (2009) 536-544
75. Feng C., et al. Suberoylanilide hydroxamic acid promotes cardiomyocyte differentiation of rat mesenchymal stem cells. Exp Cell Res (2009)
76. Morita K., et al. Histone deacetylase inhibitors promote neurosteroid-mediated cell differentiation and enhance serotonin-stimulated brain-derived neurotrophic factor gene expression in rat C6 glioma cells. J Neurosci Res 87 (2009) 2608-2614
77. Chen T.H., et al. Sodium butyrate activates ERK to regulate differentiation of mesenchymal stem cells. Biochem Biophys Res Commun 355 (2007) 913-918
78. Mitsiades C.S., et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 540-545
79. Mariadason J.M., et al. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac and curcumin and implications for chemoprevention of colon cancer. Cancer Res. 60 (2000) 4561-4572
80. Glaser K.B., et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2 (2003) 151-163
81. Drummond D.C., et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 495-528
82. Botrugno O.A., et al. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett. 280 (2009) 134-144
83. Lane A.A., et al. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. (2009)
84. Cinatl Jr. J., et al. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha. Int. J. Oncol. 20 (2002) 97-106
85. Kosugi H., et al. In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD /Shi-scid/scid mice. Jpn. J. Cancer Res. 92 (2001) 529-536
86. Jaboin J., et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. 62 (2002) 6108-6115
87. Duvic M., et al. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin. Investig. Drugs 16 (2007) 1111-1120
88. Cang S., et al. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J. Hematol. Oncol. 2 (2009) 22
89. Shimizu T., et al. Stabilized beta-catenin functions through TCF/LEF proteins and the Notch/RBP-Jkappa complex to promote proliferation and suppress differentiation of neural precursor cells. Mol. Cell Biol. 28 (2008) 7427-7441
90. Chun S.G., et al. Combined targeting of histone deacetylases and Hedgehog signaling enhances cytoxicity in pancreatic cancer. Cancer Biol. Ther. 8 (2009) 1340-1342
91. Meng, R.D. et al. (2008) Use of the Notch signaling pathway to predict disease progression and distant recurrence-free surival in early stage colon cancer. In ASCO Annual Meeting, Abstraqct No: 14500
92. Akiyoshi T., et al. Gamma-secretase inhibitors enhance taxane-induced mitotic arrest and apoptosis in colon cancer cells. Gastroenterology 134 (2008) 131-144
93. Carew J.S., et al. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 269 (2008) 7-17
94. Fuino L., et al. Histone deacetylase inhibitor LAQ824 downregulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine and epothilone B. Mol. Cancer Ther. 2 (2003) 971-984
95. Zhang Y., et al. Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino-methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int. J. Cancer 110 (2004) 301-308
96. Chung Y.L., et al. Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: implications for increasing therapeutic gain in cancer radiotherapy. Mol. Cancer Ther. 3 (2004) 317-325
97. Fan X., et al. Notch1 and Notch2 have opposite effects on embryonal brain tumor growth. Cancer Res. 64 (2004) 7787-7793
98. Arai M.A., et al. The first HES1 dimer inhibitors from natural products. Bioorg. Med. Chem. Lett. 19 (2009) 5778-5781
99. Beatty G.L., et al. Telomerase as a universal tumor antigen for cancer vaccines. Expert Rev. Vaccines 7 (2008) 881-887
100. Sasai Y., et al. Two mammalian helix-loop-helix factors structurally related to Drosophila Hairy and Enhancer of Split. Genes Dev. 6 (1992) 2620-2634
101. Murre C., et al. Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence. Cell 58 (1989) 537-544
102. Castella P., et al. HES-1 repression of differentiation and proliferation in PC12 cells: role for the helix 3-helix 4 domain in transcription repression. Mol. Cell Biol. 20 (2000) 6170-6183
103. Stockhausen M.T., et al. Regulation of the Notch target gene HES-1 by TGFalpha induced Ras/MAPK signaling in human neuroblastoma cells. Exp. Cell Res. 310 (2005) 218-228
104. Curry C.L., et al. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 24 (2005) 6333-6344